# A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

> **NCT06887192** · PHASE2 · RECRUITING · sponsor: **MapLight Therapeutics** · enrollment: 300 (estimated)

## Conditions studied

- Psychosis Associated With Alzheimer's Disease

## Interventions

- **DRUG:** ML-007C-MA
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06887192
- **Lead sponsor:** MapLight Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-15
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06887192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06887192, "A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06887192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*